HLS Therapeutics Inc.
HLTRF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -10.2% | 2.6% | 2.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 84.1% | 87.9% | 91.9% | 93.4% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 30.4% | 20.4% | 28.1% | 42% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -34.7% | -43.6% | -38.4% | -21.9% |
| EPS Diluted | -0.62 | -0.85 | -0.73 | -0.41 |
| % Growth | 27.1% | -16.4% | -78% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |